Effect of Ginkgo Diterpene Lactone Meglumine on the Quality of Life in Patients with Acute Ischemic Stroke

Overview

Journal Health Qual Life Outcomes

Publisher Biomed Central

Specialty Public Health

Date 2024 Nov 16

PMID 39548582

Authors

Xue Tian

Qin Xu

Xue Xia

Yijun Zhang

Xingquan Zhao

Anxin Wang

Affiliations

Soon will be listed here.

Abstract

Objective: Ginkgo diterpene lactone meglumine (GDLM) could improve the functional outcome after acute ischemic stroke (AIS). This study aimed to investigate the efficacy of GDLM on the quality of life in patients with AIS in China.

Methods: This is a post hoc analysis of Efficacy and Safety of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke trial. The quality of life was measured using the EuroQoL questionnaire, including EQ-5D and EQ visual analogue scale (EQ-VAS). The primary outcomes were changes in EQ-5D and EQ-VAS from baseline to day 14 and day 90 after randomization.

Results: A total of 3219 patients with completed data on outcomes were enrolled, with median age of 63 years (interquartile range, 55-70) and 2,067 (64.2%) men. GDLM was associated with a significant decrease in scores of ED-5Q components (from 0 [no problem] to 3[extreme problem]), the mean difference between GDLM and placebo group was -0.14 for mobility, -0.11 for usual activities and self-care, -0.09 for pain/discomfort, and -0.34 for anxiety/depression on day 14, respectively. Similar results were observed on day 90. Additionally, there was statistically significant difference of changes in EQ-VAS between the GDLM group and the placebo group from baseline to day 14 (mean difference, 1.70; 95% confidence interval [CI], 0.78-2.62; P = 0.0003) and to day 90 after randomization (mean difference, 3.29; 95% CI, 2.37-4.22; P < 0.001).

Conclusions: In this analysis of Chinese patients with AIS, GDLM could improve the 14-day and 90-day quality of life compared with the placebo.

Trial Registration: URL: https://www.

Clinicaltrials: gov . Unique identifier: NCT02526225. Registration Date: 2016-02-01.

References

Hill M, Goyal M, Menon B, Nogueira R, McTaggart R, Demchuk A . Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet. 2020; 395(10227):878-887. DOI: 10.1016/S0140-6736(20)30258-0. View

Niu T, Yin H, Xu B, Yang T, Li H, Sun Y . Protective Effects of Ginkgolide on a Cellular Model of Alzheimer's Disease via Suppression of the NF-κB Signaling Pathway. Appl Biochem Biotechnol. 2022; 194(6):2448-2464. PMC: 9117391. DOI: 10.1007/s12010-022-03828-5. View

Yang P, Zhang Y, Zhang L, Zhang Y, Treurniet K, Chen W . Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke. N Engl J Med. 2020; 382(21):1981-1993. DOI: 10.1056/NEJMoa2001123. View

Wang X, Zhao X, Johnston S, Xian Y, Hu B, Wang C . Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy. Neurology. 2015; 85(7):573-9. PMC: 4548281. DOI: 10.1212/WNL.0000000000001844. View

Zhao H, Guo Q, Li B, Shi M . The Efficacy and Safety of Ginkgo Terpene Lactone Preparations in the Treatment of Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Pharmacol. 2022; 13:821937. PMC: 8982077. DOI: 10.3389/fphar.2022.821937. View

Martin R, Yeatts S, Hill M, Moy C, Ginsberg M, Palesch Y . ALIAS (Albumin in Acute Ischemic Stroke) Trials: Analysis of the Combined Data From Parts 1 and 2. Stroke. 2016; 47(9):2355-9. PMC: 4995121. DOI: 10.1161/STROKEAHA.116.012825. View

Shaw J, Johnson J, Coons S . US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005; 43(3):203-20. DOI: 10.1097/00005650-200503000-00003. View

Shao L, Dong C, Geng D, He Q, Shi Y . Ginkgolide B inactivates the NLRP3 inflammasome by promoting autophagic degradation to improve learning and memory impairment in Alzheimer's disease. Metab Brain Dis. 2022; 37(2):329-341. DOI: 10.1007/s11011-021-00886-2. View

Zhang W, Song J, Yan R, Li L, Xiao Z, Zhou W . Diterpene ginkgolides protect against cerebral ischemia/reperfusion damage in rats by activating Nrf2 and CREB through PI3K/Akt signaling. Acta Pharmacol Sin. 2018; 39(8):1259-1272. PMC: 6289361. DOI: 10.1038/aps.2017.149. View

10.

Muus I, Ringsberg K . Stroke Specific Quality of Life Scale: Danish adaptation and a pilot study for testing psychometric properties. Scand J Caring Sci. 2005; 19(2):140-7. DOI: 10.1111/j.1471-6712.2005.00323.x. View

11.

Fan X, Cao Z, Liu M, Liu W, Xu Z, Tu P . Diterpene Ginkgolides Meglumine Injection inhibits apoptosis induced by optic nerve crush injury via modulating MAPKs signaling pathways in retinal ganglion cells. J Ethnopharmacol. 2021; 279:114371. DOI: 10.1016/j.jep.2021.114371. View

12.

Lyden P, Buchan A, Boltze J, Fisher M . Top Priorities for Cerebroprotective Studies-A Paradigm Shift: Report From STAIR XI. Stroke. 2021; 52(9):3063-3071. PMC: 8384700. DOI: 10.1161/STROKEAHA.121.034947. View

13.

Liu J, Ye T, Zhang Y, Zhang R, Kong Y, Zhang Y . Protective Effect of Ginkgolide B against Cognitive Impairment in Mice via Regulation of Gut Microbiota. J Agric Food Chem. 2021; 69(41):12230-12240. DOI: 10.1021/acs.jafc.1c05038. View

14.

Zhang Q, Wang A, Xu Q, Xia X, Tian X, Zhang Y . Efficacy and Safety of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke: A Randomized Clinical Trial. JAMA Netw Open. 2023; 6(8):e2328828. PMC: 10425831. DOI: 10.1001/jamanetworkopen.2023.28828. View

15.

Savitz S, Baron J, Fisher M . Stroke Treatment Academic Industry Roundtable X: Brain Cytoprotection Therapies in the Reperfusion Era. Stroke. 2019; 50(4):1026–1031. DOI: 10.1161/STROKEAHA.118.023927. View

16.

Chamorro A, Amaro S, Castellanos M, Segura T, Arenillas J, Marti-Fabregas J . Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol. 2014; 13(5):453-60. DOI: 10.1016/S1474-4422(14)70054-7. View

17.

van der Ende N, den Hartog S, Broderick J, Khatri P, Visser-Meily J, van Leeuwen N . Disentangling the Association Between Neurologic Deficits, Patient-Reported Impairments, and Quality of Life After Ischemic Stroke. Neurology. 2023; 100(13):e1321-e1328. PMC: 10065207. DOI: 10.1212/WNL.0000000000206747. View

18.

Elkins J, Veltkamp R, Montaner J, Johnston S, Singhal A, Becker K . Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 2017; 16(3):217-226. DOI: 10.1016/S1474-4422(16)30357-X. View

19.

Grool A, van der Graaf Y, Witkamp T, Vincken K, Mali W, Geerlings M . Progression of White Matter Lesion Volume and Health-Related Quality of Life in Patients with Symptomatic Atherosclerotic Disease: The SMART-MR Study. J Aging Res. 2011; 2011:280630. PMC: 3195506. DOI: 10.4061/2011/280630. View

20.

Alvarez-Sabin J, Santamarina E, Maisterra O, Jacas C, Molina C, Quintana M . Long-Term Treatment with Citicoline Prevents Cognitive Decline and Predicts a Better Quality of Life after a First Ischemic Stroke. Int J Mol Sci. 2016; 17(3):390. PMC: 4813246. DOI: 10.3390/ijms17030390. View